New partnership to tackle cancer and Alzheimer’s disease

Latest News

The National Foundation for Medical Research and Innovation (NFMRI) and Equity Trustees have announced a new partnership providing $1.29 million to advance medical innovations in the area of Alzheimer’s disease and cancer.

Equity Trustees has directed the combined resources of 24 philanthropic trusts to form a new partnership program that will inject more than $3 million over three years into health and medical research.

Other partners include the Mater Foundation and Monash Partners.

NFMRI was founded in 1977 with primary objective to support innovative areas of research with the goal of preventing or eradicating disease.

According to NFMRI CEO, Dr Noel Chambers, “He was proud NFMRI was selected as a partner following Equity Trustees’ robust selection and review process. NFMRI has worked hard to develop a unique capability and capacity to help advance medical research towards the development of new innovations including medicines, diagnostics, vaccines, devices and biologicals.”

The partnership includes around $600,000 per annum from the Mason Foundation to advance research focused on Alzheimer’s disease.

“We sought groups that have a strong focus on innovation and collaboration beyond funding, provide additional support in applying knowledge and networks to researchers to advance their careers," said Jodi Kennedy, general manager of Charitable Trusts and Philanthropy at Equity Trustees.

"NFMRI is recognised as a leader, building collaborations to support medical research and translation that will provide health benefits internationally. We look forward to sharing the learnings from the process with our clients and the broader sector.”